News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,785 Results
Type
Article (41318)
Company Profile (265)
Press Release (688184)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204836)
Career Advice (2031)
Deals (35580)
Drug Delivery (128)
Drug Development (81507)
Employer Resources (173)
FDA (16497)
Job Trends (14979)
News (346794)
Policy (32751)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (45)
Adcomms (26)
Allergies (170)
Alliances (49579)
ALS (207)
Alzheimer's disease (1777)
Antibody-drug conjugate (ADC) (434)
Approvals (16866)
Artificial intelligence (645)
Autoimmune disease (273)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (72)
Breast cancer (742)
Cancer (5728)
Cardiovascular disease (460)
Career advice (1723)
Career pathing (41)
CAR-T (319)
CDC (56)
Celiac Disease (3)
Cell therapy (862)
Cervical cancer (46)
Clinical research (70686)
Collaboration (2023)
Company closure (5)
Compensation (1371)
Complete response letters (77)
COVID-19 (2740)
CRISPR (107)
C-suite (1095)
Cystic fibrosis (150)
Data (7678)
Decentralized trials (3)
Denatured (27)
Depression (158)
Dermatology (82)
Diabetes (581)
Diagnostics (6907)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (312)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91792)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119251)
Executive appointments (1071)
FDA (20154)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1699)
Gene editing (230)
Generative AI (54)
Gene therapy (698)
GLP-1 (1046)
Government (4724)
Grass and pollen (6)
Guidances (407)
Healthcare (18981)
HIV (78)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (88)
Indications (180)
Infectious disease (3076)
Inflammatory bowel disease (215)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (287)
Interviews (319)
IPO (16665)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (38)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (755)
Lymphoma (424)
Machine learning (59)
Management (59)
Manufacturing (1016)
MASH (183)
Medical device (13914)
Medtech (14023)
Mergers & acquisitions (20150)
Metabolic disorders (1478)
mRNA (198)
Multiple sclerosis (186)
NASH (17)
Neurodegenerative disease (406)
Neuropsychiatric disorders (104)
Neuroscience (3263)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (692)
Opinion (285)
Ovarian cancer (214)
Pain (249)
Pancreatic cancer (293)
Parkinson's disease (353)
Partnered (33)
Patents (588)
Patient recruitment (658)
Peanut (62)
People (59517)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22028)
Phase 2 (31143)
Phase 3 (23176)
Pipeline (8261)
Policy (311)
Postmarket research (2568)
Preclinical (9377)
Press Release (64)
Prostate cancer (292)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1050)
Real estate (5968)
Recruiting (70)
Regulatory (25312)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (176)
Series A (285)
Series B (210)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3636)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1085)
Venture capital (106)
Weight loss (444)
Women's health (122)
Worklife (20)
Date
Today (246)
Last 7 days (939)
Last 30 days (3279)
Last 365 days (30305)
2026 (11498)
2025 (30172)
2024 (35218)
2023 (40075)
2022 (51180)
2021 (55715)
2020 (54083)
2019 (46537)
2018 (35015)
2017 (32111)
2016 (31480)
2015 (37553)
2014 (31319)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27329)
Location
Africa (741)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (39621)
Australia (6496)
California (13025)
Canada (3709)
China (1310)
Colorado (558)
Connecticut (564)
Delaware (397)
Europe (85721)
Florida (1952)
Georgia (417)
Hawaii (3)
Idaho (62)
Illinois (1037)
India (88)
Indiana (593)
Iowa (23)
Japan (521)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1566)
Massachusetts (9293)
Michigan (358)
Minnesota (704)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3434)
New Mexico (29)
New York (3408)
North Carolina (1660)
North Dakota (8)
Northern California (6511)
Ohio (388)
Oklahoma (23)
Oregon (41)
Pennsylvania (2626)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5137)
Tennessee (209)
Texas (2060)
United States (45995)
Utah (390)
Vermont (1)
Virginia (311)
Washington D.C. (80)
Washington State (1046)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
729,785 Results for "chimerix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
Chimerix announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock.
April 16, 2024
·
1 min read
Business
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Chimerix reported financial results for the first quarter ended March 31, 2024 and provided an operational update.
May 1, 2024
·
9 min read
Press Releases
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 5, 2025
·
14 min read
Press Releases
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
March 21, 2025
·
7 min read
Bio NC
Chimerix to Participate in Fireside Chat at Jefferies 2024 Global Healthcare Conference
Chimerix announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
May 30, 2024
·
1 min read
Deals
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock.
November 24, 2023
·
1 min read
Business
Chimerix Appoints Marc D. Kozin to Board of Directors
Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors.
March 21, 2024
·
2 min read
Mergers & acquisitions
Jazz Expands Cancer Expertise With $935M Chimerix Buy
At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.
March 5, 2025
·
2 min read
·
Tristan Manalac
Business
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
Chimerix reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
February 29, 2024
·
9 min read
Press Releases
Chimerix to Speak Today at The White House Cancer Moonshot Forum
January 14, 2025
·
3 min read
1 of 72,979
Next
